AstraZeneca (AZN) reported Q1 core earnings Tuesday of $2.49 per diluted share, up 21% from a year earlier.
Analysts polled by FactSet expected $2.24.
Revenue for the quarter ended March 31 was $13.59 billion, compared with $12.68 billion a year earlier.
Analysts surveyed by FactSet expected $13.81 billion.
The company reiterated its 2025 core earnings guidance of a low double-digit percentage increase. Analysts surveyed by FactSet expect $9. Meanwhile, full-year revenue is still expected to increase by a high single-digit percentage. Analysts polled by FactSet expect $57.68 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。